Phosphodiesterase-5 inhibitors and hearing impairment: a disproportionality analysis using the US food and drug administration adverse event reporting system.

Min LuoTianqi LiuXiangtong YeBingjie XiaoRuonan GaoRonghai CuiBin Wu

Published in: Expert opinion on drug safety (2024)

These findings highlight a significant correlation between PDE-5i use and HIAEs, emphasizing the need for careful evaluation in clinical practice and providing appropriate guidance to patients before initiating treatment.

Keyphrases

clinical practice
end stage renal disease
drug administration
newly diagnosed
chronic kidney disease
adverse drug
patient reported outcomes
human health
patient reported